BB BIOTECH AG

  • WKN: A0NFN3
  • ISIN: CH0038389992
  • Land: Switzerland

Nachricht vom 19.02.2021 | 07:00

BB Biotech AG publishes its 2020 annual report

DGAP-News: BB BIOTECH AG / Key word(s): Annual Results/Dividend
19.02.2021 / 07:00
The issuer is solely responsible for the content of this announcement.

Media release as of February 19, 2021

Annual report of BB Biotech AG as of December 31, 2020

BB Biotech AG publishes its 2020 annual report

BB Biotech AG published its annual report for fiscal year 2020 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the biotechnology sector, BB Biotech's positioning, the investment areas covered by its portfolio and the companies it is invested in.

BB Biotech performed well in a volatile market environment. For the full year, total share return was 19.3% in CHF and 18.1% in EUR and the portfolio performance was 24.3% in CHF, and 24.8% in EUR. The consolidated and audited full year 2020 data showed a net gain of CHF 691 mn compared to a net gain of CHF 677 mn for 2019.

As already announced on January 22, 2021, BB Biotech will propose a dividend of CHF 3.60 per share at the upcoming Annual General Meeting, which represents a yield of 5% based on the volume-weighted average price of BB Biotech shares in December 2020. This marks a continuation of the dividend policy of the previous years.

BB Biotech's annual report 2020 is available under report.bbbiotech.ch/2020/en resp. www.bbbiotech.com.

For further information:

Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Dr. Silvia Siegfried-Schanz, ssc@bellevue.ch
Maria-Grazia Iten-Alderuccio, mga@bellevue.ch
Claude Mikkelsen, cmi@bellevue.ch

Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch

TE Communications AG, St. Leonhard-Strasse 45, 9000 St. Gallen, Switzerland, tel. +41 79 423 22 28
Thomas Egger, teg@te-communications.ch

www.bbbiotech.com

Company profile
BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in Switzerland, Germany and Italy. Since 1993, the company has invested in innovative drug development companies that are mainly located in the US and Western Europe. BB Biotech is one of the leading investors in this sector. BB Biotech builds on the long-standing experience of its distinguished Board of Directors and on the fundamental analysis of the experienced Investment Management Team of Bellevue Asset Management AG when making its investment decisions.



19.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

Landi Renzo: GBC-Interview mit CEO Christiano Musi

„Der Landi Renzo-Konzern ist ein globaler Akteur, der sich auf die Energiewende entlang der gesamten Wertschöpfungskette spezialisiert hat und darauf abzielt, ein weltweiter Referenzpunkt für RNG- und Wasserstoffanwendungen bei Green Mobility und Clean-Tech-Lösungen zu werden. Bis 2025 erwarten wir Umsatzzuwächse von 15% (CAGR) und ein zweistelliges EBITDA-Wachstum von 25% (CAGR), dank ansteigender Umsätze in Segmenten, die im Vergleich zu unserem traditionellen Markt für leichte Nutzfahrzeuge höhere Margen aufweisen."

Events im Fokus

Termine 2022

12./13. Oktober 2022: Fachkonferenz Finanzdienstleistungen/Technologie

News im Fokus

Henkel AG & Co. KGaA: Henkel steigert Umsatz deutlich, treibt strategische Agenda voran und hebt Umsatzprognose für 2022 an

15. August 2022, 07:30

Aktueller Webcast

HomeToGo SE

Webcast Link

16. August 2022

Aktuelle Research-Studie

APONTIS PHARMA AG

Original-Research: Apontis Pharma AG (von Montega AG): Kaufen

16. August 2022